Physician profile
Jarod E Speer
NPI 1609947993
$16,827.59
in general payments reported to CMS, 2019-2025
45 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $1,223 · 2021: $1,895 · 2022: $2,494 · 2023: $3,095 · 2024: $3,567 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,276.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,146.19 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $1,946.05 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,690.02 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,407.98 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,158.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $737.85 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $705.50 | 2019-2025 | |
| Amgen INC. | $656.71 | 2019-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $599.95 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.87 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $570.64 | 2019-2022 | |
| Abbott Laboratories | $472.73 | 2021-2025 | Freestyle Libre, Proclaim |
| Novartis Pharmaceuticals Corporation | $369.32 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $368.62 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $303.90 | 2024-2025 | Ibsrela |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $267.83 | 2023-2025 | Accrufer |
| Ironwood Pharmaceuticals, INC | $238.38 | 2020-2024 | Linzess |
| Allergan, INC. | $205.84 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $199.57 | 2021-2025 | Gvoke Hypopen |
| Mylan Specialty L.P. | $195.92 | 2019-2024 | Yupelri |
| Dexcom, INC. | $189.00 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $184.53 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $176.82 | 2022-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $171.60 | 2022 | |
| Amarin Pharma, INC. | $168.23 | 2021-2022 | |
| Exact Sciences Corporation | $163.49 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $159.41 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $74.11 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $71.74 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $69.92 | 2022-2024 | Austedo, Austedo Xr |
| Ucb, INC. | $66.64 | 2023 | Briviact |
| Astellas Pharma US INC | $59.68 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $58.90 | 2021-2024 | Verquvo |
| Esperion Therapeutics, INC. | $53.35 | 2020-2024 | Nexletol |
| Arbor Pharmaceuticals, INC. | $48.61 | 2019-2020 | |
| Lundbeck LLC | $42.56 | 2025 | Rexulti |
| Sanofi Pasteur INC. | $40.60 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $39.98 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $37.03 | 2021 | |
| Nevro Corp. | $28.44 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $24.99 | 2020-2023 | Seglentis, Livalo |
| Alkermes, INC. | $20.68 | 2023 | Aristada, Lybalvi |
| Eisai INC. | $17.68 | 2022 | |
| Pulmonx Corporation | $17.46 | 2021 | |
| Genentech USA, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarod Speer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.